Earned Wealth Advisors LLC Has $1.76 Million Stock Position in Eli Lilly and Company $LLY

Earned Wealth Advisors LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.3% during the second quarter, Holdings Channel.com reports. The firm owned 2,252 shares of the company’s stock after selling 437 shares during the period. Earned Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,755,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LLY. Brighton Jones LLC lifted its stake in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd lifted its holdings in Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after acquiring an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $242,000. Finally, Golden State Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 9.1% during the first quarter. Golden State Wealth Management LLC now owns 1,019 shares of the company’s stock worth $842,000 after acquiring an additional 85 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LLY. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Guggenheim restated a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $936.47.

Eli Lilly and Company Stock Up 3.5%

Shares of LLY opened at $842.28 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm’s 50-day simple moving average is $777.69 and its 200 day simple moving average is $770.84. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $797.18 billion, a P/E ratio of 55.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the company posted $1.18 EPS. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.